Botanix Pharmaceuticals Limited

ASX:BOT Stock Report

Market Cap: AU$97.6m

Botanix Pharmaceuticals Future Growth

Future criteria checks 2/6

Botanix Pharmaceuticals is forecast to grow earnings and revenue by 74.4% and 70.6% per annum respectively. EPS is expected to grow by 87.2% per annum. Return on equity is forecast to be -16.9% in 3 years.

Key information

74.4%

Earnings growth rate

87.22%

EPS growth rate

Pharmaceuticals earnings growth48.9%
Revenue growth rate70.6%
Future return on equity-16.94%
Analyst coverage

Low

Last updated16 Apr 2026

Recent future growth updates

Recent updates

Bullish View That A Scalable Dermatology Platform Will Transform An Underserved Hyperhidrosis Market

Catalysts About Botanix Pharmaceuticals Botanix Pharmaceuticals is a dermatology company focused on commercialising Sofdra for primary axillary hyperhidrosis and leveraging its U.S. commercial platform. What are the underlying business or industry changes driving this perspective?

Single Product And API Constraints Will Shape Dermatology Platform Potential Over The Long Term

Catalysts About Botanix Pharmaceuticals Botanix Pharmaceuticals is a dermatology company focused on Sofdra, a prescription treatment for primary axillary hyperhidrosis supported by its own fulfillment platform. What are the underlying business or industry changes driving this perspective?

Long-Term Hyperhidrosis Demand And Fulfillment Platform Will Support This Bullish Thesis

Catalysts About Botanix Pharmaceuticals Botanix Pharmaceuticals is a dermatology company focused on Sofdra, a prescription treatment for primary axillary hyperhidrosis. What are the underlying business or industry changes driving this perspective?

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Dec 10
Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Mar 21
Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Sep 06
Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Jan 03
Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Sep 05
Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

May 10
Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

Jan 12
We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth

Jul 01
We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Mar 18
We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Jan 24
The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Nov 30
We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Earnings and Revenue Growth Forecasts

ASX:BOT - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20281471653
6/30/202775-34-15-173
6/30/202637-63-55-563
12/31/202522-89-78-78N/A
9/30/202514-88-79-78N/A
6/30/20256-86-80-79N/A
3/31/20254-63-59-57N/A
12/31/20242-39-39-35N/A
9/30/20242-27-33-22N/A
6/30/20242-14-26-8N/A
3/31/20241-12-26-9N/A
12/31/20230-10-27-10N/A
9/30/20232-10-23-11N/A
6/30/20234-9-19-12N/A
3/31/20235-10-20-12N/A
12/31/20226-11-20-12N/A
9/30/20225-12-17-12N/A
6/30/20223-13-14-11N/A
3/31/20221-12-8-7N/A
12/31/20210-11-2-2N/A
9/30/20213-7-3-3N/A
6/30/20217-3-3-3N/A
3/31/20217-6-6-6N/A
12/31/20207-9-8-8N/A
9/30/20207-13-13-13N/A
6/30/20208-17-17-17N/A
3/31/20208-18-21-21N/A
12/31/20198-20-24-24N/A
9/30/20196-18N/A-19N/A
6/30/20195-17N/A-13N/A
3/31/20195-15N/A-12N/A
12/31/20185-13N/A-10N/A
9/30/20183-12N/A-10N/A
6/30/20182-11N/A-10N/A
3/31/20182-8N/A-8N/A
12/31/20172-6N/A-7N/A
9/30/20171-5N/A-6N/A
6/30/2017N/A-5N/A-5N/A
12/31/2016N/A-3N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BOT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BOT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BOT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BOT's revenue (70.6% per year) is forecast to grow faster than the Australian market (6.4% per year).

High Growth Revenue: BOT's revenue (70.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BOT is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/20 12:48
End of Day Share Price 2026/04/20 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Botanix Pharmaceuticals Limited is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madeleine WilliamsCanaccord Genuity
Joseph PantginisH.C. Wainwright & Co.